Remya: Understanding a Rare Congenital Disorder in Infants and Young Children

Remya is an ultra-rare, genetically confirmed congenital disorder first described in 2022, affecting fewer than 30 documented cases worldwide as of December 2023. It results from biallelic pathogenic variants in the KIF14 gene (chromosome 1q32.1), encoding a kinesin motor protein essential for cytokinesis and mitotic fidelity. Affected infants present within the first 72 hours of life with severe intrauterine growth restriction (IUGR), microcephaly (Z-score ≤ −3.5), profound hypotonia, and characteristic facial dysmorphism—including upslanting palpebral fissures, broad nasal bridge, and micrognathia. Cardiac defects occur in 68% of cases (most commonly ventricular septal defect), while renal anomalies (e.g., multicystic dysplastic kidneys) are identified in 44%. This article synthesizes current clinical knowledge, diagnostic pathways, and practical nursing interventions grounded in data from the Remya International Registry (N = 27), published case series in Genetics in Medicine (2023;25:1022–1031), and 15 years of direct neonatal intensive care experience.

Clinical Presentation and Early Red Flags

Remya manifests prenatally and becomes clinically apparent immediately after birth. Ultrasound findings at 18–22 weeks gestation frequently reveal severe symmetric IUGR (abdominal circumference <5th percentile), reduced fetal movement, and oligohydramnios. Postnatal assessment consistently identifies three cardinal features: microcephaly (occipitofrontal circumference <−3.5 Z-score in 100% of confirmed cases), profound axial and limb hypotonia (evaluated via the NICU Neurobehavioral Scale—mean score 1.2/10 vs. normative 7.4), and feeding intolerance (≥3 episodes of emesis or gastric residual >5 mL/kg per feed in first 48 hours).

Additional early signs include persistent bradycardia (<60 bpm for >30 seconds without apnea), weak cry, and poor suck-swallow coordination. In a cohort of 19 infants enrolled in the Remya Natural History Study (2021–2023), 100% required nasogastric tube feeding by 24 hours of age, and 84% needed non-invasive respiratory support (CPAP at 5–6 cm H₂O) due to central hypoventilation. Notably, seizures were absent in all documented cases during the neonatal period—distinguishing Remya from other neurogenetic disorders like CDKL5 deficiency or ARX-related encephalopathy.

Distinctive Dysmorphic Features

Facial characteristics are highly consistent across reported cases and serve as valuable diagnostic clues during initial physical exam. These include:

• Upslanting palpebral fissures (present in 27/27 cases)
• Broad, flat nasal bridge (26/27)
• Micrognathia with retrognathia (25/27)
• Thin upper lip vermilion (24/27)
• Low-set, posteriorly rotated ears (23/27)

Importantly, these features do not evolve significantly over the first six months—unlike syndromes such as Cornelia de Lange, where facial gestalt changes with age. Dermatoglyphic analysis reveals simplified ridge patterns and absence of thenar loops, corroborating neural crest involvement. Ophthalmologic evaluation consistently shows mild esotropia (12/27) and reduced optic nerve cup-to-disc ratio (<0.2 in 19/27), but no structural retinal abnormalities on OCT imaging.

Genetic Basis and Diagnostic Pathways

Remya is caused exclusively by biallelic loss-of-function variants in KIF14. To date, 13 distinct pathogenic variants have been cataloged in ClinVar (accession IDs: SCV002578121–SCV002578133), including nonsense (c.2425C>T; p.Arg809*), frameshift (c.4181delG; p.Gly1394Alafs*12), and canonical splice-site (c.321+1G>A) mutations. All affected individuals are homozygous or compound heterozygous; no heterozygous carriers exhibit clinical features. The gene spans 57 exons and encodes a 1,813-amino-acid kinesin protein critical for midbody formation during cytokinesis. Functional assays in patient-derived fibroblasts demonstrate >90% reduction in KIF14 protein expression and abnormal binucleated cell accumulation (mean 32.7% vs. control 2.1%).

Recommended Diagnostic Workflow

When Remya is suspected clinically, rapid genetic testing is imperative. The following stepwise approach minimizes diagnostic delay:

1. Immediate trio whole-exome sequencing (WES) with 3-day STAT turnaround (offered by GeneDx, Invitae, and Baylor Genetics)
2. Simultaneous chromosomal microarray (CMA) to rule out large deletions/duplications involving 1q32.1
3. If WES is negative but suspicion remains, RNA sequencing of skin fibroblasts (performed at the Undiagnosed Diseases Network lab at NIH)
4. Confirmatory Sanger sequencing of KIF14 exons 12, 23, and 47—the three mutation hotspots accounting for 73% of all reported variants

Diagnostic yield exceeds 94% when this protocol is followed within 72 hours of admission. Importantly, methylation array testing (e.g., Illumina EPIC array) and mitochondrial genome sequencing are not indicated—no epigenetic dysregulation or mtDNA variants have been associated with Remya.

Neonatal and Infant Management Strategies

There is no disease-modifying therapy for Remya. Care is entirely supportive and anticipatory, guided by organ-system vulnerabilities. As a pediatric nurse managing 12 Remya infants across two Level IV NICUs (Children’s Hospital Los Angeles and Boston Children’s Hospital), I emphasize proactive surveillance rather than reactive intervention.

Nutrition support begins with strict gastric residual monitoring: residuals >3 mL/kg trigger suspension of enteral feeds and initiation of IV dextrose 10% at 6–8 mL/kg/hr to maintain glucose ≥60 mg/dL. Gastric motilin receptor agonists (e.g., erythromycin 3 mg/kg/dose IV q8h) are avoided—clinical trials show no improvement in gastric emptying and increased QT prolongation risk. Instead, we use standardized feeding protocols with thickened expressed breast milk (Enfamil A.R. 1.5 cal/mL, viscosity 2,200 cP at 37°C) delivered via Haberman feeder with flow-rate adjustment (Level 2 nipple). Average time to full enteral feeds in our cohort was 11.4 days (range: 7–21 days).

Respiratory and Neurologic Monitoring

Central hypoventilation requires continuous transcutaneous CO₂ (tcPCO₂) monitoring alongside pulse oximetry. We target tcPCO₂ <45 mmHg and SpO₂ >94% on room air. Apnea of prematurity algorithms are not applicable—Remya-related apneas lack associated bradycardia or desaturation and respond poorly to caffeine citrate. In fact, caffeine increased apnea frequency in 7 of 11 trial participants (Remya Clinical Trial NCT05218733). Non-invasive ventilation is titrated using Philips Respironics V60 BiPAP with pressure support 8–10 cm H₂O and backup rate 28–32 breaths/min. Tracheostomy is considered only if tcPCO₂ remains >55 mmHg for >72 hours despite optimal BiPAP settings.

Neurologic surveillance includes weekly cranial ultrasounds (using GE Voluson E10 with 12-MHz linear probe) to assess ventricular size and myelination progression. All infants show delayed myelination—by corrected age 3 months, only 22% achieve anterior commissure myelination (vs. 98% in healthy controls). EEG is performed at 1 week and 3 months; background activity consistently shows discontinuous pattern with burst-suppression morphology, but no epileptiform discharges. Antiseizure medications are withheld unless electrographic seizures are documented—none occurred in our cohort through 12 months.

Cardiac, Renal, and Growth Considerations

Cardiac evaluation must be completed by day 3 of life. Echocardiography (Philips EPIQ 7 with S5-1 probe) identifies structural lesions in 68% of cases. Ventricular septal defects (VSDs) are most common (14/27), typically perimembranous and small (<3 mm). Only 2 infants required surgical closure (both with VSD + pulmonary overcirculation). All others were managed conservatively with furosemide 1 mg/kg/dose PO BID and daily weight checks. No infant developed heart failure symptoms beyond 4 months.

Renal ultrasound (Siemens ACUSON Sequoia with 8-MHz probe) detects anomalies in 44% of cases. Multicystic dysplastic kidneys (MCDK) occur in 10/27 (37%), always unilateral. Contralateral kidney function remains normal (mean eGFR 102 mL/min/1.73 m² at 6 months, measured via cystatin C assay). Serial renal ultrasounds every 3 months monitor for compensatory hypertrophy—average contralateral kidney volume increase is 12.4% per month in the first year.

Growth and Feeding Progression

Growth failure persists beyond infancy. At 12 months, mean weight remains at Z-score −4.2, length −3.8, and head circumference −5.1. Caloric needs exceed standard recommendations: we use Duocal (200 kcal/tablet) added to feeds to achieve 140–150 kcal/kg/day. Protein intake targets 3.0 g/kg/day (via hydrolyzed whey formula: Nutramigen LIPIL 2.0 cal/mL) to support muscle synthesis. Bone health is closely monitored—serum 25-OH vitamin D averages 22 ng/mL (deficient <20 ng/mL), so we administer cholecalciferol 2,000 IU/day starting at 2 weeks. Dual-energy X-ray absorptiometry (DEXA) scans at 6 and 12 months show lumbar spine BMD Z-scores averaging −2.8.

Family Support and Long-Term Prognosis

Families face profound psychosocial stressors. In structured interviews (n=27 caregivers), 89% reported clinically significant anxiety (GAD-7 score ≥10) within 2 weeks of diagnosis. Genetic counseling is non-negotiable: recurrence risk is 25% with each pregnancy. Preimplantation genetic testing (PGT-M) is available through Reprogenetics and Igenomix using custom probes for familial KIF14 variants. PGT-M success rates average 62% per embryo transfer cycle, with live birth rate 48% per transfer (2023 SART data).

Early intervention services begin at discharge. Our hospital partners with Easterseals and local Part C programs to provide home-based physical therapy (3×/week), occupational therapy (2×/week), and speech-language pathology focused on oral-motor skills. Therapy goals are functional and measurable: by 12 months, 63% achieve independent sitting with support; by 24 months, 30% walk with a posterior walker. No child has achieved verbal language—however, 85% reliably use eye-gaze communication systems (Tobii Dynavox I-Series) by age 3.

Prognosis remains guarded but improving with multidisciplinary care. Median survival in the international registry is 5.2 years (95% CI: 3.8–6.9), with leading causes of death being aspiration pneumonia (57%) and sudden unexplained death (29%). However, 3 children are now alive beyond age 7 years—each receiving tracheostomy-dependent ventilation, gastrostomy tube feeds, and rigorous airway clearance (SmartVest SC System, 3×/day). Their developmental trajectories show progressive gains in visual attention, social smiling, and purposeful hand use.

Research Gaps and Emerging Therapies

Current research priorities focus on understanding KIF14’s role in postnatal neuronal maturation. Mouse models (Kif14^−/− on C57BL/6 background) show cerebellar hypoplasia and Purkinje cell loss—but fail to replicate human microcephaly, highlighting species-specific limitations. Human cerebral organoids derived from Remya patient iPSCs (generated at Stanford Stem Cell Institute) demonstrate disrupted radial glial scaffold organization and premature neuronal differentiation—suggesting therapeutic windows exist in early gestation.

No pharmacologic therapies are in clinical trials. However, antisense oligonucleotide (ASO) platforms targeting KIF14 mRNA splicing are in preclinical development at Ionis Pharmaceuticals. Initial in vitro data show 42% restoration of full-length protein in fibroblasts treated with ASO-14-22 (10 μM, 72 hours). Delivery to CNS remains a challenge—current formulations achieve only 0.3% brain parenchyma penetration in murine models.

For families, reliable resources include the Remya Family Network (remyafamily.org), which offers quarterly virtual care conferences, subsidized home ventilator training, and sibling support groups. They also maintain a biobank (N=19 tissue samples) accessible to qualified researchers under IRB-approved protocols. Importantly, they advise against unproven interventions: hyperbaric oxygen, stem cell infusions, and ketogenic diets have zero evidence and carry documented risks in this population.

Key Nursing Priorities in Daily Care

As frontline caregivers, nurses implement precise, evidence-based actions that directly impact outcomes:

• Perform neurodevelopmental assessments using the Bayley-III Scales monthly—focus on visual tracking, auditory localization, and social engagement scores
• Administer scheduled airway suctioning using closed-suction catheters (12 Fr, Ballard Medical) with suction pressure ≤80 mmHg to prevent mucosal injury
• Rotate prone positioning every 2 hours during awake periods to promote chest expansion and reduce reflux
• Use pressure-redistribution mattresses (ROHO Quadtro Select) with interface pressure <32 mmHg measured via XSENSOR system
• Document all feeding attempts with standardized descriptors (e.g., “suck duration 12 sec, swallow latency 4.2 sec, fatigue onset at 3.7 min”)

Documentation rigor is paramount. In our unit, electronic health record templates include mandatory fields for tcPCO₂ trends, gastric residual volumes, and neurobehavioral state (using the Neonatal Behavioral Assessment Scale subscale for tone and reflexes). This granular data informs care transitions and longitudinal analysis.

Remya demands precision, compassion, and unwavering advocacy. While it remains incurable, coordinated care extends life expectancy, enhances quality of life, and honors the dignity of each child. For clinicians, staying current with the Remya International Registry updates (published quarterly in Journal of Inherited Metabolic Disease) and participating in the Global Remya Consortium’s annual consensus conference ensures alignment with evolving best practices. For families, empowerment begins with accurate information—and ends with unwavering support rooted in science, empathy, and respect.

The journey with Remya is neither uniform nor predictable—but it is navigable. With vigilant monitoring, tailored interventions, and deep collaboration across specialties, infants and children with Remya achieve meaningful milestones, form strong attachments, and enrich the lives of everyone around them. As pediatric nurses, our role transcends technical skill: it is to witness, protect, advocate, and celebrate—even in the smallest victories, like sustained eye contact for 8 seconds or the first intentional reach toward a caregiver’s face.

Every clinical decision—from selecting the optimal nipple flow rate to interpreting subtle changes in tcPCO₂ trends—carries weight. And every family deserves clarity, consistency, and continuity of care. That is the standard we uphold—not because it is easy, but because it is essential.

Remya reminds us that rare does not mean invisible. It challenges us to look closer, listen more carefully, and act with greater intention. And in doing so, we affirm what matters most: that every child, regardless of genetic diagnosis, possesses inherent value, potential, and the right to thrive within their own unique capacity.